Theravance Biopharma - TBPH Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TBPH shares.
View TBPH analyst ratings or view top-rated stocks.

2 brokers have issued twelve-month price targets for Theravance Biopharma's shares. Their TBPH share price forecasts range from $14.00 to $19.00. On average, they anticipate the company's share price to reach $16.50 in the next twelve months. This suggests a possible upside of 56.8% from the stock's current price.
View analysts price targets for TBPH or view top-rated stocks among Wall Street analysts.

Theravance Biopharma's stock was trading at $11.22 at the beginning of the year. Since then, TBPH stock has decreased by 6.2% and is now trading at $10.52.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our TBPH earnings forecast.

Theravance Biopharma, Inc. (NASDAQ:TBPH) released its earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported ($0.48) EPS for the quarter, topping analysts' consensus estimates of ($0.60) by $0.12. The biopharmaceutical company had revenue of $13.19 million for the quarter, compared to analyst estimates of $13.55 million. Theravance Biopharma had a negative trailing twelve-month return on equity of 93.49% and a net margin of 1,698.54%. During the same period last year, the company earned ($1.16) EPS.

ETFs with the largest weight of Theravance Biopharma (NASDAQ:TBPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco Nasdaq Future Gen 200 ETF (QQQS), SPDR S&P Pharmaceuticals ETF (XPH), Global X Aging Population ETF (AGNG), iShares U.S. Pharmaceuticals ETF (IHE), Principal Healthcare Innovators ETF (BTEC) and iShares Micro-Cap ETF (IWC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL), SCYNEXIS (SCYX), Teva Pharmaceutical Industries (TEVA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Idera Pharmaceuticals (IDRA), Pfizer (PFE) and TG Therapeutics (TGTX).

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

Theravance Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (1.69%), Two Sigma Investments LP (1.43%), Bank of America Corp DE (1.30%), Millennium Management LLC (1.00%), Norges Bank (0.81%) and Charles Schwab Investment Management Inc. (0.77%). Insiders that own company stock include Brett K Haumann, Philip D Worboys, Rhonda Farnum, Richard A Graham and Rick E Winningham.
View institutional ownership trends.

Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TBPH stock can currently be purchased for approximately $10.52.

Theravance Biopharma (NASDAQ:TBPH) has a market capitalization of $665.18 million and generates $51.35 million in revenue each year. The biopharmaceutical company earns $872.13 million in net income (profit) each year or $11.54 on an earnings per share basis.

The company employs 359 workers across the globe.

Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The official website for the company is www.theravance.com. The biopharmaceutical company can be reached via phone at (650) 808-6000 or via email at investor.relations@theravance.com.